4.6 Article

Cost-effectiveness of running a paediatric oncology unit in Ethiopia

期刊

BMJ OPEN
卷 13, 期 3, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2022-068210

关键词

Health economics; Health policy; Paediatric oncology

向作者/读者索取更多资源

The study aims to estimate the cost-effectiveness of running a pediatric oncology unit in Ethiopia to provide decision support for the revision of the Ethiopia Essential Health Service Package (EEHSP). A decision tree model was used to compare the cost and effectiveness of running a pediatric oncology unit with no pediatric oncology care. The results showed that the incremental cost and DALYs averted per child treated in the pediatric oncology unit were USD 876 and 2.4, respectively. The incremental cost-effectiveness ratio was USD 361 per DALY averted, indicating that running a pediatric oncology unit is cost-effective in Ethiopia.
ObjectiveTo estimate the cost-effectiveness of running a paediatric oncology unit in Ethiopia to inform the revision of the Ethiopia Essential Health Service Package (EEHSP), which ranks the treatment of childhood cancers at a low and medium priority.MethodsWe built a decision analytical model-a decision tree-to estimate the cost-effectiveness of running a paediatric oncology unit compared with a do-nothing scenario (no paediatric oncology care) from a healthcare provider perspective. We used the recently (2018-2019) conducted costing estimate for running the paediatric oncology unit at Tikur Anbessa Specialized Hospital (TASH) and employed a mixed costing approach (top-down and bottom-up). We used data on health outcomes from other studies in similar settings to estimate the disability-adjusted life years (DALYs) averted of running a paediatric oncology unit compared with a do-nothing scenario over a lifetime horizon. Both costs and effects were discounted (3%) to the present value. The primary outcome was incremental cost in US dollars (USDs) per DALY averted, and we used a willingness-to-pay (WTP) threshold of 50% of the Ethiopian gross domestic product per capita (USD 477 in 2019). Uncertainty was tested using one-way and probabilistic sensitivity analyses.ResultsThe incremental cost and DALYs averted per child treated in the paediatric oncology unit at TASH were USD 876 and 2.4, respectively, compared with no paediatric oncology care. The incremental cost-effectiveness ratio of running a paediatric oncology unit was USD 361 per DALY averted, and it was cost-effective in 90% of 100 000 Monte Carlo iterations at a USD 477 WTP threshold.ConclusionsThe provision of paediatric cancer services using a specialised oncology unit is most likely cost-effective in Ethiopia, at least for easily treatable cancer types in centres with minimal to moderate capability. We recommend reassessing the priority-level decision of childhood cancer treatment in the current EEHSP.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据